Monopar Therapeutics Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Monopar Therapeutics Inc. (MNPR) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$13.64 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-27
- Monopar Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$13.64M.
- Monopar Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$15.49M.
- Monopar Therapeutics Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$8.38M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$13.64M 10-K · filed 2026-03-27 |
| 2024-12-31 | -$15.49M 10-K · filed 2026-03-27 |
| 2023-12-31 | -$8.38M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |